(NASDAQ: WHWK) Whitehawk Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.05%.
Whitehawk Therapeutics's earnings in 2026 is -$83,294,000.On average, 11 Wall Street analysts forecast WHWK's earnings for 2026 to be -$55,427,137, with the lowest WHWK earnings forecast at -$59,563,666, and the highest WHWK earnings forecast at -$52,665,516. On average, 10 Wall Street analysts forecast WHWK's earnings for 2027 to be -$52,464,886, with the lowest WHWK earnings forecast at -$61,298,531, and the highest WHWK earnings forecast at -$42,752,007.
In 2028, WHWK is forecast to generate -$49,496,734 in earnings, with the lowest earnings forecast at -$68,816,275 and the highest earnings forecast at -$30,360,121.